Mesoblast Earnings, Revenue Miss in Q3
- ByInvesting.com-
Investing.com - Mesoblast (NASDAQ:MESO) reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Mesoblast...
Investing.com - Mesoblast (NASDAQ:MESO) reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Mesoblast...
Investing.com - Mesoblast (NASDAQ:MESO) reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that topped expectations. Mesoblast announced...
Investing.com - Mesoblast (NASDAQ:MESO) reported on Thursday first quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Mesoblast...
Novartis NVS and partner Incyte (NASDAQ:INCY) INCY announced that the late-stage study on ruxolitinib in COVID-19 patients was not successful.The phase III RUXCOVID study is a...
This week, the biotech sector was in focus with updates from biotechs evaluating their pipeline drugs and vaccines for the treatment of COVID-19. A new strain of coronavirus, which...
For Immediate ReleaseChicago, IL – January 20, 2020 – Stocks in this week’s article are China Distance Education Holdings Ltd. (NYSE:DL) , Intellicheck...
Mesoblast Limited is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Sell | Sell | Sell | Sell | Strong Sell |
Technical Indicators | Sell | Sell | Buy | Sell | Strong Sell |
Summary | Sell | Sell | Neutral | Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
37.94 | 38.46 | 36.70 | +0.20 | +0.53% | 7.97M | NYSE | |||
8.34 | 8.56 | 8.02 | +0.51 | +6.51% | 9.12M | NYSE | |||
1.13 | 1.14 | 1.06 | +0.0300 | +2.73% | 7.70M | NYSE | |||
0.1985 | 0.2009 | 0.174 | +0.0235 | +13.43% | 2.90M | NYSE | |||
4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
125.88 | 127.32 | 124.13 | +0.64 | +0.51% | 4.22M | NASDAQ | |||
96.67 | 100.69 | 95.09 | +0.39 | +0.41% | 141.06M | NASDAQ | |||
0.0001 | 0.0001 | 0.0001 | 0.00000 | 0.00% | 0.00 | OTC Markets | |||
9.86 | 9.86 | 9.86 | -0.04 | -0.39% | 700.00 | NASDAQ | |||
46.33 | 47.54 | 44.28 | +1.01 | +2.23% | 5.08M | NYSE | |||
9.92 | 9.924 | 9.91 | 0.000 | 0.00% | 0.00 | NYSE | |||
10.07 | 10.07 | 10.07 | +0.14 | +1.36% | 100.00 | NASDAQ | |||
6.38 | 6.51 | 6.21 | +0.07 | +1.11% | 252.30K | NASDAQ | |||
78.99 | 78.99 | 77.82 | -0.21 | -0.27% | 1.34K | NASDAQ | |||
15.25 | 15.46 | 14.42 | +0.50 | +3.39% | 645.88K | NYSE |